According to a recent LinkedIn post from BioSpectator Inc, Hanmi Pharmaceutical is reportedly pursuing development of an oral EP300-targeting targeted protein degradation (TPD) therapy positioned for solid tumors. The post notes that EP300 and CBP drug programs have traditionally focused on hematologic malignancies, based on the tumor-promoting role of histone acetyltransferase activity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that Hanmi is seeing early in vivo efficacy signals without observing thrombocytopenia, a toxicity that has been cited as a limitation for EP300/CBP dual inhibitors. It also relays comments from Hanmi researcher Dr. Nam Ho-yeon at AACR 2026, who pointed to oral bioavailability and structural differentiation as key potential advantages of Hanmi’s EP300 degrader.
According to the post, Hanmi is developing an oral EP300 degrader that binds both EP300 and cereblon (CRBN), and is currently in the lead optimization stage. The content also indicates that machine learning is being used to refine indication selection in solid tumors, suggesting a data-driven approach to clinical strategy.
For investors following the targeted protein degradation space, the post suggests incremental competitive pressure and innovation around EP300 as a target, particularly in solid tumors where options remain limited. If Hanmi’s approach can maintain efficacy while mitigating thrombocytopenia and enabling oral dosing, competing or partnering companies in oncology and TPD could face both partnering opportunities and heightened competition over time.